Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Famitinib in Healthy Subjects
NCT05046808Phase 1Completed
- Sponsor
- Hengrui
- Start
- Sep 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of famitinib in solid tumor (5 arms), sponsored by Hengrui. Primary endpoints: Maximum observed plasma concentration for Famitinib, Area under the plasma concentration versus time curve (AUC0-t) for Famitinib and 12 more. Started Sep 2021; status: completed.
02
Drugs
famitinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05046808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05046808.